Immunotherapy comes to the fore in treatment of mRCC

Treatment of people with metastatic renal clear cell carcinoma (mRCC) has evolved rapidly over the last decade, according to a snapshot of Australian prescribing that highlights the increasing uptake of immune checkpoint inhibitors and newer tyrosine kinase inhibitors (TKIs). A review of PBS data from March 2010 to March 2020 showed that sunitinib had remained ...

Already a member?

Login to keep reading.

© 2022 the limbic